![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Real Hotel Grp | LSE:RHG | London | Ordinary Share | GB00B3D2NR11 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.875 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:5505V James Reed & Partners PLC 13 December 2005 This announcement is not for release, publication or distribution in or into or from the United States, Canada, Australia, Japan or any other jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction. For immediate release 13 December 2005 Reed Health Group plc ("Reed Health") Recommended Increased Offers declared wholly unconditional The board of James Reed & Partners plc ('James Reed & Partners' or 'JRP') announces that by 3.00 p.m. (UK time) on 12 December 2005, the first closing date of the Recommended Increased Offers, valid acceptances of the Recommended Increased Offers had been received in respect of a total of 14,915,688 Reed Health Ordinary Shares and 26,830,580 Reed Health 'B' Shares representing approximately 45.47 per cent. of the Reed Health Ordinary Shares and approximately 99.96 per cent. of the Reed Health 'B' Shares respectively and, in aggregate, approximately 69.99 per cent. of the issued share capital, and voting rights, of Reed Health. The above total includes acceptances in respect of 8,367,542 Reed Health Ordinary Shares and 26,827,500 Reed Health 'B' Shares, representing, in aggregate, approximately 59.01 per cent of the issued share capital, and voting rights, of Reed Health, pursuant to irrevocable undertakings to accept the Recommended Increased Offers from the Independent Directors of Reed Health and certain other Reed Health Shareholders. In addition, JRP owns 15,780,125 Reed Health Ordinary Shares representing approximately 48.11 per cent. of the issued Reed Health Ordinary Shares and approximately 26.46 per cent. of the issued share capital, and voting rights, of Reed Health. Therefore, JRP either owns, or has received valid acceptances of the Recommended Increased Offers over, a total of 57,526,393 Reed Health Shares, representing, in aggregate, approximately 96.45 per cent. of the issued share capital, and voting rights, of Reed Health. Save as disclosed in this announcement, neither JRP, nor any persons acting, or deemed to be acting, in concert with JRP, held any Reed Health Shares (or rights over Reed Health Shares) or has acquired or agreed to acquire any Reed Health Shares (or rights over Reed Health Shares) during the Offer Period. In accordance with the terms and conditions of the Recommended Increased Offers, the board of JRP announces that all outstanding conditions of the Recommended Increased Offers have either been satisfied or waived and that the Recommended Increased Offers are therefore declared unconditional in all respects. The Recommended Increased Offers will remain open for acceptance until further notice. JRP intends to procure that Reed Health applies to the London Stock Exchange and the FSA for the cancellations, respectively, of the trading of Reed Health Ordinary Shares on the London Stock Exchange and the listing of the Reed Health Ordinary Shares on the Official List. It is anticipated that such cancellations will, subject to the Listing Rules and the Rules of the FSA, take effect no earlier then 13 January 2006, being 20 business days after the date of this announcement that the Recommended Increased Offers are declared unconditional in all respects. To the extent they have not already done so, Reed Health Shareholders who hold their Reed Health Shares in certificated form and who wish to accept the Recommended Increased Offers should complete, sign and return their Further Forms of Acceptance as soon as possible in accordance with the instructions set out in the Original Offer Document, the Recommended Increased Offer Document and in the Further Forms of Acceptance. Reed Health Ordinary Shareholders who hold their Reed Health Ordinary Shares in uncertificated form and who wish to accept the Recommended Increased Ordinary Offer should send a TTE Instruction to CRESTCo in relation to such shares as soon as possible. The procedure for acceptance of the Recommended Increased Ordinary Offer is set out in paragraph 18 of Part II of the Recommended Increased Offer Document. In accordance with paragraph 14 of Part II of the Recommended Increased Offer Document, JRP will today post proposals to the holders of options under the Reed Health Share Option Schemes in relation to the Recommended Increased Offers. As valid acceptances have been received in respect of more than nine-tenths in value of the Reed Health 'B' Shares to which the Recommended Increased 'B' Ordinary Offer relates, JRP intends to apply the provisions of sections 428 to 430F of the Companies Act to acquire compulsorily any outstanding Reed Health 'B' Shares not acquired or agreed to be acquired by or on behalf of JRP pursuant to the Recommended Increased 'B' Ordinary Offer or otherwise. Accordingly JRP will shortly be posting formal notices pursuant to section 429(4) of the Companies Act 1985 to those Reed Health 'B' Shareholders who have not validly accepted the Recommended Increased 'B' Ordinary Offer. Once valid acceptances have been received in respect of more than nine-tenths in value of the Reed Health Ordinary Shares to which the Recommended Increased Ordinary Offer relates, JRP also intends then to apply the provisions of sections 428 to 430F of the Companies Act to acquire compulsorily any outstanding Reed Health Ordinary Shares not acquired or agreed to be acquired by or on behalf of JRP pursuant to the Recommended Increased Ordinary Offer or otherwise. Words and expressions defined in the Original Offer Document dated 10 November 2005 and the Recommended Increased Offer Document dated 24 November 2005 shall have the same meaning when used in this announcement. Copies of the documents, posted to Reed Health Shareholders on 10 November 2005 and 24 November 2005 respectively, are available for inspection at Mayer, Brown, Rowe & Maw LLP, 11 Pilgrim Street, London, EC4U 6RW. Enquiries: James Reed & Partners plc James Reed / Derek Beal Tel: 020 8274 4467 Altium Capital Limited Garry Levin / Tim Richardson / Marc Milmo Tel: 020 7484 4040 Smithfield Consultants Reg Hoare / Katie Hunt Tel: 020 7360 4900 Altium Capital Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for James Reed & Partners as financial adviser within the meaning of the Rules of the Financial Services Authority and for no one else in connection with the Recommended Increased Offers. Altium Capital Limited is not advising any other person or treating any other person as its client in relation thereto and will not be responsible to anyone other than James Reed & Partners for providing the protections afforded to clients of Altium Capital Limited, or for giving advice to any other person in relation to the Recommended Increased Offers, the contents of this announcement or any other matter referred to herein. This information is provided by RNS The company news service from the London Stock Exchange EN OUPTTBLTMMBBBPA
1 Year Reed Health Chart |
1 Month Reed Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions